Medable

09/01/2026

Launching an AI pilot is one thing. Turning it into measurable value across clinical operations is another challenge entirely.

This Thursday, join us to explore what separates experimentation from successful adoption and how structured digital foundations can help agents work effectively across clinical workflows.

We’ll show it in practice with live demos and real deployment results from top pharma across digital data flow, clinical monitoring, and TMF management.

See what agentic AI is already delivering and what it takes to scale it.

👉 Save your spot here: https://webinarsreg.endpoints.news/how-leading-pharma-organizations-are-putting-ai-agents-to-work/
________

09/01/2026

We're excited to share the impact of our Total Consent solution in a US women’s health study on menopause managed by ICON plc. Beating expectations, more than 85% of trial participants, or 1,044 out of 1,222, consented using Medable’s enhanced eConsent technology. Additionally, 18 sites achieved 100% eConsent adoption among participants. With Medable, ICON aims to expand its use of advanced clinical trial technologies, reflecting broader momentum across the clinical research ecosystem, including the FDA, toward more real-time and technology-enabled trials.

👉 Learn more here: https://www.medable.com/newsroom/medable-and-icon-exceed-patient-econsent-adoption-goals-for-womens-health-study-on-menopause?utm_source=linkedin&utm_medium=organic&utm_campaign=&utm_content=
________

Medable and ICON exceeded eConsent adoption goals in a U.S. menopause study, with more than 85% of participants consenting electronically and 18 sites achieving 100% adoption.

08/28/2026

Your clinical teams shouldn’t have to be experts at navigating disconnected systems just to get their jobs done.
Yet too often, critical context is siloed, leaving people to search, reconcile, and piece together what they need before they can act.

Medable connects the clinical and enterprise platforms your teams already rely on, creating a secure, compliant flow of information across the study ecosystem so decisions can happen faster.

Start with pre-built connectors, onboard with minimal IT effort, and add new integrations in weeks as your needs evolve.

One connected foundation for more intelligent clinical development.
_______

08/28/2026

Every clinical trial participant is making an investment in a future they may never personally benefit from. They take part not only in the hope of what a study might mean for them, but for the people who will face the same diagnosis years from now. Medable’s Patient and Caregiver Network (PCN) understands the significance of that choice, and is working to honor it by making the trial experience better for every person who chooses to take part. 💜
________

08/27/2026

Is AI actually proving its worth in clinical development yet? According to a new Tufts CSDD analysis in oncology, the answer is yes: up to $21 million in net financial value and 82x ROI for a single phase 3 program.

Check out this interview with Ken Getz and Pamela Tenaerts to uncover what an AI clinical monitoring agent can deliver with humans still firmly in the loop: https://www.pharmavoice.com/news/ai-finally-proving-worth-drug-rd-tufts/828783/
_______

A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?

08/27/2026

The cardiometabolic space isn’t slowing down. Trials are becoming more complex, portfolios are expanding, and the expectation to move faster without compromising quality is only growing.

At Medable, we’ve built a platform—and a partnership model—designed to meet these demands.

See how we've helped 5 biopharma and CRO organizations achieve unprecedented success, from faster study starts to market-leading eCOA adherence to elevated patient and site satisfaction.

👉 Download the eBook:

See how Medable helped sponsors and CROs cut study startup by 50%, hit >95% eCOA adherence, and scale weight-loss and diabetes trials faster in this book of cardiometabolic case studies.

08/14/2026

Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical monitoring agent can deliver 82x the ROI in oncology trials.

The report also found that the AI tool can deliver net financial gains as high as $21 million per drug development program.

Analyzing Medable’s clinical monitoring agent, the study looked at expected net present value (eNPV), a method for quantifying the financial impact of innovation investments.

👉 Learn more here: https://www.fiercebiotech.com/cro/ai-clinical-monitoring-agents-can-deliver-82-times-roi-report
________

A new analysis from the Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical monitoring agent can deliver 82 times the return on investment (ROI) in oncology trials. | A new analysis from the Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical m...

08/05/2026

Funding pressure, the patent cliff, smaller sponsors, and rising AI expectations are all converging at the same time. Together, they're forcing CROs to rethink a commercial model that has barely changed in decades. The next generation of market leaders won't simply automate more work—they'll build operating models that turn AI into a structural cost advantage.

👉 Learn more here: https://www.medable.com/knowledge-center/blog-the-future-economics-of-cros
________

07/31/2026

Every day a clinical trial runs inefficiently is another day patients wait longer for the answers they deserve. That's what drives everything we do at Medable, and it's why we've embedded AI into the heart of clinical trial operations to accelerate drug development. We're proud to be named a 2026 Fierce AI Innovation Awards Finalist—and even more motivated to keep pushing what's possible. 📈 🚀
________

07/30/2026

Every major evolution in clinical monitoring has followed the same pattern: identify inefficiencies, redesign the process, and ask CRAs to do more with less. It worked for a while, but we've reached the point where process improvements alone can't keep pace with the complexity of modern trials.

Agentic AI represents something fundamentally different. Rather than changing how monitoring is organized, it changes how the work gets done, freeing CRAs to spend more time applying clinical judgement and less time acting as the integration layer between disconnected systems.

👉 Learn more here: https://www.medable.com/knowledge-center/blog-rapid-evolution-how-agentic-ai-is-redefining-the-role-of-the-cra
________